Wave Life Sciences Ltd. (WVE)
How Much Upside is Left in Wave Life Sciences (WVE)? Wall Street Analysts Think 89.71%
The mean of analysts' price targets for Wave Life Sciences (WVE) points to an 89.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
The Federal Reserve rate cuts have sent the market up, but some stocks are rising more than others. That includes small pharmaceutical companies like Wave Life Sciences WVE, whose shares rose 9% the day after the central bank reduced rates by 50 basis points.
WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study
Wave Life Sciences stock soars 53% on positive interim data from a mid-stage study showing superior efficacy of investigational DMD drug, WVE-N531.
Wave Life Sciences' stock soars 51% after biotech posts positive data from Duchenne muscular-dystrophy trial
Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular dystrophy.
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
The Federal Reserve rate cuts have sent the market up, but some stocks are rising more than others. That includes small pharmaceutical companies like Wave Life Sciences NASDAQ: WVE, whose shares rose 9% the day after the central bank reduced rates by 50 basis points.
Wave Life Sciences Ltd. (WVE) Q2 2024 Earnings Call Transcript
Wave Life Sciences Ltd. (NASDAQ:WVE ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Erik Ingelsson - Chief Scientific Officer Conference Call Participants Tiago Fauth - Wells Fargo Joseph Schwartz - Leerink Partners Steven Seedhouse - Raymond James Luca Issi - RBC Salim Syed - Mizuho Joon Lee - Truist Operator Good morning, and welcome to the Wave Life Sciences Second Quarter 2024 Financial Results Conference Call.
Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates
Wave Life Sciences (WVE) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.20 per share a year ago.
What's Going On With Wave Life Sciences Stock On Tuesday?
Wave Life Sciences Ltd WVE announced results from its Phase 1b/2a SELECT-HD trial of WVE-003, which is being developed as a potential disease-modifying therapeutic for Huntington's disease (HD).
